DOW JONES NEWSWIRES The U.S. Justice Department has asked Cephalon Inc. (CEPH) about documents relating to alleged off-label promotion of its Treanda treatment for chronic lymphocytic leukemia, the pharmaceutical industry news site Pharmalot.com reported Monday. The June request to the Pennsylvania-based drug maker concerned first-line treatment of non-Hodgkin's lymphoma, for which Treanda isn't approved, according to sources familiar with the request. Also requested were clinical studies that could be used to support off-label use before the studies were completed or submitted for review by the U.S. Food and Drug Administration. A Cephalon spokeswoman declined to comment, Pharmalot.com reported. Israeli drug maker Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV) is attempting to complete a $6.2 billion acquisition of Cephalon, and has said it expects the deal to be completed during the third quarter, pending approval by U.S. and European regulators as well as Cephalon shareholders. Full story at http://www.pharmalot.com/2011/07/feds-probe-cephalon-for-off-label-treanda-promotion/ -Dow Jones Newswires; 212-416-2900
